Materials and Instrumentation. All reagents and solvents were obtained from commercial suppliers and used without further purification. 2-Chlorotrityl resin (1.55 mmol/g) was obtained from CBL (Patras, Greece). Amino acids were purchased from NeoMPS (Strasbourg, France). All reactions were performed under a dry atmosphere of argon using oven-dried glassware. Tetrahydrofuran, toluene and ethyl ether were distilled from sodium benzophenone ketal. Dichloromethane and DMF were distilled from calcium hydride. All other solvents were HPLC grade. Reactions were magnetically stirred and monitored by thin layer chromatography (TLC) with E. Merck silica gel 60-F254 plates. The peptide was synthesized manually in a 30 ml fritted glass tube. RP-HPLC analyses were carried out on a Macherey-Nagel C 4 column (5 µm, 150 × 4.6 mm) using a linear gradient of A: 0.1% TFA in water and B: 0.08% TFA in acetonitrile, 0-100% B in 20 min at 1.2 mL/min flow rate. Chromatograms were recorded on a Varian ProStar 330 photodiode array detector. LC-MS was performed on a Finnigan LCQ Advantage MAX.
Infrared spectra (IR) were measured on a Perkin Elmer Spectrum One ATR-FT-IR Spectrometer. UVVis-NIR spectra were recorded on a Varian Cary 5000. 1 H and 13 C NMR spectra were recorded on Bruker DPX 300 spectrometer, the peak values were given as ppm (δ), using the tetramethylsilane or the residual deuterated solvent protons as reference. Chromatographic purifications were done with silica gel Merck (Kiesegel 60, 40-60 µm, 230-400 mesh ASTM) in standard column. Transmission electron microscopy (TEM) analyses were performed on a TEM Hitachi 600 HS. TGA was performed under N 2 using a TGA Q500 analyzer (TA Instruments) by equilibrating at 100 °C and then following a ramp of 10 °C/min up to 900 °C. Other abbreviations used are: Boc, tert-butyloxycarbonyl; BOP, benzotriazole-1-yl-oxy-tris-(dimethylmino)-phosphonium hexafluorophosphate; DIEA, diisopropylethylamine; Fmoc: 9-fluorenylmethyloxycarbonyl; HFIP: 1,1,1,3,3,3-hexafluoro-2-propanol.
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Synthesis of Boc-Gly-Phe-Leu-Gly-OH (5).
The peptide was prepared on 2 mmol of 2-chlorotrityl resin (1.3 gr). Two-fold excess of Fmoc-Gly-OH in 12 ml of DCM/DMF 5:1 was added to the resin, followed by 6 eq. of DIEA. The resin was shaken 5 hours at room temperature. After elimination of the solution, the resin was re-suspended in 10 ml DCM/MeOH 1:1 for 30 min. The resin was washed and the Fmoc group was removed using 20% piperidine in DMF (10 ml) for 15 min. The treatment was repeated twice. Five-fold excess of Fmoc-Leu-OH in DMF (10 ml), activated with BOP/DIEA at a 1:1:3 ratio, was added and the resin shaken for 5 h.
The coupling was repeated using three-fold excess overnight. The resin was washed and the Fmoc group was removed using 20% piperidine in DMF (10 ml) for 15 min. This treatment was repeated twice.
Three-fold excess of Fmoc-Phe-OH in DMF (10 ml), activated with BOP/DIEA at a 1:1:3 ratio, was added and the resin shaken for 3 h. The coupling was repeated using two-fold excess for 2 h. The resin was washed and the Fmoc group was removed using 20% piperidine in DMF (10 ml) for 15 min. This treatment was repeated twice. Five-fold excess of Boc-Gly-OH in DMF (10 ml), activated with BOP/DIEA at a 1:1:3 ratio, was added and the resin shaken overnight. Completeness of each coupling was confirmed by negative Kaiser test. Cleavage of the final peptide from the resin was done using 10 ml of distilled DCM:HFIP (3:2) at room temperature for 2 h. The cleavage mixture was evaporated and the peptide was re-precipitated from diethyl ether and recovered by filtration as pale yellow solid (763 mg, 95% yield). Synthesis of methotrexate-α-hexanoic acid linker (6). 
Synthesis of 6-(tert-butyldimethylsilyloxy)hexanoic acid (10).
To a solution of 9 (2.0 g, 15.2 mmol) in dry DMF (20 mL), imidazole (2.48 g, 36.4 mmol) was added. 
Synthesis of benzyl 6-(tert-butyldimethylsilyloxy)hexanoate (11).
To a solution of 10 (3.4 g, 13.6 mmol), in Acetone (60 mL), potassium carbonate (9.4 g, 68.2 mmol) was added and after 10 min benzyl bromide (2.1 mL, 17.7mmol) was added dropwise. The reaction was brought to reflux and stirred until TLC analysis c-Hexane-AcOEt (5:1) showed the complete conversion (6 h). The reaction was cooled at room temperature and filtrated, the excess of solvents was removed under vacuum and the crude oil product (4.4 g, 96%) was sufficiently pure for following step. 
Synthesis of benzyl 6-hydroxyhexanoate (12).
To 
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Synthesis of methotrexate γ-tert-butyl α-n-hexylbenzyl ester (14).
To a solution of 1-(6-(Benzyloxy)-6-oxohexyl) 
Synthesis of methotrexate γ-tert-butyl α-n-hexanoic acid (6). 
Synthesis of t-Boc-NH-triethylenglicole-sulfonamide-rhodamine B (17).
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Synthesis of rhodamine B sulfonamide-N-triethylenglicole hydrochloride (7).
O N N + S O O NH O O N H O O SO 3 - 17 O N N + S O O NH O O NH 3 + Cl -
Synthesis of ox-MWNT (19).
Pristine MWNTs 18 (1 g), (p-MWNTs, Nanocyl 3100, Batch n° 071005) were sonicated in a water bath 
Synthesis of MWNT (1).
A To a suspension of MWNT 1 (8 mg, 1.8 µmol), in dry DMF (2.5 mL), DIPEA (21 µL, 70 eq.) and HATU (10 mg, 15 eq.) were added. Subsequently, MTX (10 mg, 12 eq.) was added and the reaction was stirred at 60 °C under Ar atmosphere for 50 h. The crude product was purified by centrifugation-precipitation, using step gradient centrifugation DMF-MeOH, MeOH, MeOH-Et 2 O, to thoroughly remove excess of organic reactants. The absence of free MTX was confirmed by TLC analysis and finally dried under vacuum (7.1 mg). The amount of MTX was estimated via quantitative Kaiser test (see Table S1 ). MWNT 2, were also characterized by TEM and TGA (see Supplementary Figures) . Table S1 ).
To a suspension of amine-functionalized MWNT 22, (9.3 mg, 1.0 µmol) in dry DMF (2.5 mL), DIPEA (10 µL, 70 eq.) and HATU (8 mg, 25 eq.) were added. Subsequently, MTX (7 mg, 18 eq.) was added and the reaction was stirred at 60 °C under Ar atmosphere for 50 h. The crude product was purified by centrifugation-precipitation, using step gradient centrifugation DMF-MeOH, MeOH, MeOH-Et 2 O, to thoroughly remove excess of organic reactants. The absence of free MTX was confirmed by TLC analysis and HPLC (supernatant) (see Figure S8 ), finally dried under vacuum, to afford MWNT 3 (8.5 mg). The amount of MTX was estimated via quantitative Kaiser test (see Table S1 ). MWNT 3, were also characterized by TEM and TGA (see Supplementary Figures) . To a suspension of MWNT 23, (5.6 mg) in dry DMF (2 mL), DIPEA (24 µL, 50 eq.) and HATU (10 mg, 10 eq.) were added. Subsequently, Rhodamine B Sulfonamide-N-triethylenglicole hydrochloride 7 (8 mg, 4 eq.) was added and the reaction was stirred at 60 °C under Ar atmosphere for 50 h. The crude product was purified by centrifugation-precipitation, using DMF-MeOH, MeOH, MeOH-Et 2 O, to thoroughly remove excess of organic reactants. The absence both of free MTX and Rhodamine was confirmed by TLC analysis and HPLC analysis of the supernatant (see Figure S8 ) and finally dried under vacuum (5.1 mg). The amount of MTX was estimated via quantitative Kaiser test (see Table S1 ). MWNT 4, were also characterized by TEM and TGA (see Supplementary Figures) . The peak at 5.509 min corresponds to the commercially available MTX (Apollo Scientific LTD; Lot n. 40138). Subsequent dilutions (starting from 0.02 mg/ml to 0.2 µg/ml) display the decrease of MTX peak.
The HPLC detection limit of the MTX is lower than 0.5 µg/ml. This concentration is 10-fold lower than the concentration of the free MTX tested for its cytotoxic activity on MCF-7 cells (4.54 µg/ml -10 µM, see Figure 4 of the main text). 
Cell Culture and Confocal Microscopy studies

